A study led by the Barcelona Institute for Global Health (ISGlobal) and Aarhus University shows that children and adolescents diagnosed with attention-deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) in Denmark today share more characteristics with their peers in the general population than those diagnosed a decade ago.

Not all cancer cells are the same, and neither are their responses to drugs. Finding the right drug for the right cancer cell is a long battle in drug development and in designing effective treatments. A new AI tool called ProteinTalks makes this task easier by accurately predicting whether a drug will be effective against a cancer cell line, finding new drug combinations and identifying proteins linked to drug resistance.

Researchers at Texas A&M University's Naresh K. Vashisht College of Medicine have identified time-specific patterns of brain activity following ketamine treatment in older adults with treatment-resistant depression.

A new study published in The American Journal of Pathology provides new evidence that immune cells enter the retina via the body's standard pathway, identifying PECAM as the gatekeeper and neutrophils as proresolving mediators. This research offers new insights into how eye inflammation develops and could lead to better-targeted treatment options.

Cystic fibrosis, one of the most common genetic diseases in Switzerland, promotes chronic bacterial infections by impairing the protective barrier of the airways. Scientists at the University of Geneva (UNIGE) have discovered that this dysfunction is caused by the abnormal activation of a protein, connexin 43, which disrupts cellular organization and compromises the integrity of the airways.

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase III IZABRIGHT-Lung01 registrational study.

Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase III IMpower030 trial.

Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase Ib/II BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated small cell lung cancer (SCLC), according to results from the randomized Phase II DeLLphi-309 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).